Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2321Neoplasms 1683Prostatic Neoplasms 1180Lung Neoplasms 911Colorectal Neoplasms 876Carcinoma, Non-Small-Cell Lung 851Leukemia, Myeloid, Acute 587Pancreatic Neoplasms 568Multiple Myeloma 542Carcinoma, Hepatocellular 511Brain Neoplasms 510Neoplasm Metastasis 457Head and Neck Neoplasms 454Melanoma 410Ovarian Neoplasms 404Glioblastoma 398Precursor Cell Lymphoblastic Leukemia-Lymphoma 390Stomach Neoplasms 370Uterine Cervical Neoplasms 357Squamous Cell Carcinoma of Head and Neck 357Rectal Neoplasms 337Recurrence 332Hematologic Neoplasms 324Sarcoma 322Colonic Neoplasms 317Lymphoma 311Triple Negative Breast Neoplasms 284Urinary Bladder Neoplasms 279Carcinoma, Renal Cell 279Glioma 278

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Small Intestine Cancer × 1 year × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡